New in CME Courses: GLP-1 RA and Basal Insulin: Individualizing Therapy for Clinical Practice​

New Online CME Activity and Live Expert Faculty Webinar

Target audience:  Primary Care Providers, Nurse Practitioners, Physician Assistants.

New agents and combinations of agents – such as SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor agonists (RA), and fixed-ratio basal insulin/GLP-1 RAs – have been approved for the treatment of type 2 diabetes (T2DM) in recent years. These novel agents effectively reduce hyperglycemia and have lower risk for some common side effects of established therapies.

Despite the availability of multiple effective medical therapies, patients with T2DM are often inadequately managed and may have persistent hyperglycemia for years before the intensification of treatment. What is the role for new agents to improve glycemic control in these patients?

In this unique game-style activity, you will participate in the management of a virtual patient with T2DM and rank therapeutic options at each decision point. Expert faculty will rank the same options and provide an evidence-based rationale for their choices.

After the last of these decision points, join the faculty for a live webinar in which they will address your questions regarding the management of patients with T2DM.

Join the live session on July 25, 2017, at 1:00 PM ET (10:00 AM PT, 11:00 AM MT) to interact with faculty experts:

 

Mark E. Molitch, MD
Martha Leland Sherwin Professor of Endocrinology
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL

 

Lyle D. Mitzner, MD
Assistant Professor of Medicine, Harvard Medical School
Attending Physician in Endocrinology, Beth Israel Deaconess Medical Center
Staff Physician, Joslin Diabetes Center
Boston, MA

 

This activity, GLP-1 RA and Basal Insulin: Individualizing Therapy for Clinical offers 1.5 AMA PRA Category 1 Credit™.

Click here to start this engaging activity and join the live webinar on July 25th!